16-186 - Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer
Status: openA randomized Phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer
Treatment for Cervical Cancer
Contact Us
If you have questions about this trial or are interested in participating, please contact Wendy Blount, director of clinical trials, at (251) 445-9834 or wlblount@health.southalabama.edu.
Description
The purpose of this study is to evaluate the safety and effectiveness of immunotherapy in combination with chemotherapy and radiation (chemoradiation) for the treatment of advanced cervical cancer. Pembrolizumab, a type of immunotherapy called a checkpoint inhibitor, will be administered after or during chemoradiation. IRB Number 16-186
Sponsors
This trial is sponsored by Merck.Providers Associated With This Trial
Principle Investigator
Sub Investigators
![Rocconi Rodney]()
View ProfileRodney P. Rocconi, M.D., F.A.C.O.G.Gynecologic OncologistAssociate Director for Clinical Research; Professor of Interdisciplinary Clinical Oncology
This link will open in a new tab or window.